In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
W. Kevin Kelly, DO
Advertisement
Articles by W. Kevin Kelly, DO
We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.
Advertisement
Latest Updated Articles
COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?December 17th 2018
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Considering Venlafaxine as Distress Treatment in Breast Cancer
5